EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)

Clinico-radiological outcomes after discontinuation of sorafenib in non-abdominal desmoid-type fibromatosis: Final results from a phase-II SORASTOP study from India

Kinjal Singh, Sameer Rastogi, Akash Singh, Simran Kaur, Shivanand Gamanagatti, Stanzin Spalkit, Ghazal Tansir, Bharath B Gangadharaiah, Vikas Garg, Adarsh Barwad, Sandeep Bhoriwal, Puneet Tanwar

European Journal of Cancer · 2026

DOI: 10.1016/j.ejca.2026.116253 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift European Journal of Cancer, 2026. Verfasst von Kinjal Singh und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi 110029, India. Hauptthemen laut MEDLINE: Sorafenib, Desmoid Tumors, Antineoplastic Agents, Protein Kinase Inhibitors. Die Arbeit nennt 26 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: The SORASTOP study reports long-term outcomes following planned sorafenib discontinuation in responding patients with extremity desmoid-type fibromatosis (DTF). MATERIALS AND METHODS: In this prospective, single-arm phase 2 Simon's two-stage trial, adults with non-progressive, extremity DTF, ESAS pain 5. The primary endpoint was 1-year PFS. RESULTS: 33 patients (median age 30 years; 54.5 % female) were enrolled between 2021-2023. At 12 months, 31 (93.9 %) were evaluable; at 24 months, 30 (90.9 %). After 12 months of discontinuation, 4/31 (12.9 %) had PR, 24/31 (77.4 %) SD and 3/31 (9.6 %) PD and at 24 months 8/30 (26.6 %) had PR, 16/30 (53.3 %) SD and 6/30 (20 %) PD (RECIST v1.1). ESAS pain showed a transient rise: pain-free patients (ESAS=0) decreased from 69.7 % at baseline to 35.5 % at 12 months, recovering to 66.7 % at 24 months. Nine patients (27 %) progressed; four required sorafenib re-initiation and five were managed conservatively, all ultimately achieving disease stabilisation. PFS at 12, 24 and 36 months were 90.8 %, 74.5 % and 74.5 % respectively; with median follow-up of 37 months. EORTC QLQ-C30 showed stable global health status and improvements in emotional, physical, and cognitive functioning, with reductions in fatigue and pain. CONCLUSION: Planned sorafenib discontinuation in responding extremity DTF patients is feasible, yields durable disease control, and improves QoL. Patients who progressed were successfully managed with sorafenib re-challenge or observation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SorafenibDesmoid TumorsAntineoplastic AgentsProtein Kinase InhibitorsHumansFemaleAdultMaleProspective StudiesIndiaTreatment InterruptionYoung AdultMiddle Aged

Stichwörter der Autor:innen

Desmoid-type fibromatosisEdmonton symptom assessment System (ESAS) Pain ScoreProgression-free survival (PFS)Quality of life (EORTC QLQ-C30)SorafenibTreatment discontinuationTyrosine Kinase Inbibitors (TKIs)

Substanzen

SorafenibAntineoplastic AgentsProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Department of Medical Oncology, Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi 110029, India.
  • Department of Medical Oncology, Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi 110029, India. Electronic address: samdoc_mamc@yahoo.com.
  • Department of Physiology, All India Institute of Medical Sciences, New Delhi 110029, India.
  • Department of Radio-diagnosis, Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi 110029, India.
  • Department of Pathology, All India Institute of Medical Sciences, New Delhi 110029, India.
  • Department of Surgical Oncology, Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi 110029, India.

Zitieren

APA

Singh, K., Rastogi, S., Singh, A., Kaur, S., Gamanagatti, S., Spalkit, S., Tansir, G., Gangadharaiah, B. B., Garg, V., Barwad, A., Bhoriwal, S., & Tanwar, P. (2026). Clinico-radiological outcomes after discontinuation of sorafenib in non-abdominal desmoid-type fibromatosis: Final results from a phase-II SORASTOP study from India. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2026.116253

Vancouver

Singh K, Rastogi S, Singh A, Kaur S, Gamanagatti S, Spalkit S, et al. Clinico-radiological outcomes after discontinuation of sorafenib in non-abdominal desmoid-type fibromatosis: Final results from a phase-II SORASTOP study from India. European Journal of Cancer. 2026. doi:10.1016/j.ejca.2026.116253

BibTeX
@article{Singh2026,
  author = {Singh, Kinjal and Rastogi, Sameer and Singh, Akash and Kaur, Simran and Gamanagatti, Shivanand and Spalkit, Stanzin and Tansir, Ghazal and Gangadharaiah, Bharath B and Garg, Vikas and Barwad, Adarsh and Bhoriwal, Sandeep and Tanwar, Puneet},
  title = {Clinico-radiological outcomes after discontinuation of sorafenib in non-abdominal desmoid-type fibromatosis: Final results from a phase-II SORASTOP study from India},
  journal = {European Journal of Cancer},
  year = {2026},
  doi = {10.1016/j.ejca.2026.116253}
}
Kostenlos starten →